Athenex
ATNX

Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will effect a 1-for-20 reverse stock split of its issued common stock, effective at 12:01 a.m. Eastern Time on February 15, 2023.

From June 30, 2022 to September 30, 2022 Sale of common stock through public offering, net of costs of $1,173 Vesting of restricted stock units Sale of common stock through ESPP Treasury stock repurchase Sale of common stock through ATM, net of costs of $49

1.Common stock being offered by 35,333,334 shares of common stock 2.The number of shares of common stock to be outstanding immediately after this offering is based on 121,742,763 shares outstanding as of August 10, 2022

From March 31, 2022 to June 30, 2022 Sale of common stock through ATM, net of costs of $86 Sale of common stock through ESPP

From January 1, 2022 to March 31, 2022 Sale of common stock through ATM, net of costs of $52

From December 31, 2020 to December 31, 2021 Sale of common stock through ATM and ESPP, net of costs of $35 Issuance of stock in connection with acquisition of Kuur Issuance of common stock in connection with Cidal contingent consideration Stock options exercised Treasury stock repurchase

From June 30, 2021 to September 30, 2021 Issuance of common stock in connection with Cidal acquisition

From March 31, 2021 to June 30, 2021 Issuance of common stock in connection with acquisition of Kuur and settlement of transaction incentive liability assumed Stock options exercised Sale of common stock

From January 1, 2020 to March 31, 2021 Restricted stock expense Stock options exercised

from December 31, 2019 to December 31, 2020 Sale of common stock, net of costs of $7,869 Restricted stock expense Stock options exercised

From June 30, 2020 to September 30, 2020 Sale of common stock and issuance of stock in connection with acquisition Restricted stock expense Stock options exercised

1.Common stock offered by the company 10,000,000 shares of common stock. 2.The number of shares of common stock to be outstanding immediately after this offering, as stated above, is based on 81,689,534 shares outstanding as of June 30, 2020.

From March 31, 2020 to June 30, 2020 Sale of common stock and issuance of stock in connection with acquisition Stock options exercised

From December 31, 2019 to March 31, 2020 Restricted stock expense Stock options exercised

From December 31, 2018 to December 31, 2019 Sale of common stock, net of costs and discounts of $907 Vesting of restricted stock Stock options and warrants exercised Research and development licensing fee satisfied with stock

from June 30, 2019 to September 30, 2019 Sale of common stock, net of costs and discounts of $907 Vesting of restricted stock Stock options and warrants exercised Research and development licensing fee satisfied with stock

from March 31, 2019 to June 30,2019 Sale of common stock, net of costs of $54 Stock-based compensation cost Stock options exercised

from January 1, 2019 to March 31, 2019 Stock options and warrants exercised

from December 31, 2017 to December 31, 2018 Sale of common stock, net of costs and discounts of $5,518 Vesting of restricted stock Stock options and warrants exercised Research and development license purchased with stock

from December 31, 2017 to September 30, 2018 Sale of common stock, net of costs and discounts of $5,518 Vesting of restricted stock Stock options and warrants exercised Research and development license purchased with stock

from December 31, 2017 to June 30, 2018 Sale of common stock, net of costs and discounts of $4,611 Vesting of restricted stock Stock options and warrants exercised Research and development licensing fee satisfied with stock

from December 31, 2017 to March 31, 2018 Sale of common stock, net of costs and discounts of $4,611 Stock options and warrants exercised

from December 31, 2016 to December 31, 2017 Sale of common stock, net of costs and discounts of $11,706 Conversion of bonds Stock-based compensation cost Research and development licensing fee satisfied with stock Vesting of restricted stock Stock options and warrants exercised Repurchase of common stock

from December 31, 2016 to September 30, 2017 Sale of common stock, net of costs and discounts of $11,706 Conversion of bonds Stock-based compensation cost Research and development licensing fee satisfied with stock Vesting of restricted stock Stock options and warrants exercised Repurchase of common stock

from December 31, 2016 to June 30, 2017 Sale of common stock, net of costs and discounts of $11,706 Conversion of bonds Stock-based compensation cost Research and development licensing fee satisfied with stock Vesting of restricted stock Stock options and warrants exercised Repurchase of common stock

1.Common stock offered by us 6,000,000 shares 2.Unless otherwise expressly stated elsewhere in this prospectus, the number of shares of our common stock to be outstanding after this offering is based on (i) 41,348,568 shares of our common stock outstanding as of March 31, 2017, which includes 661,982 issued but unvested restricted shares, (ii) 7,727,273 shares of our common stock to be issued upon the completion of this offering pursuant to the automatic conversion of $68.0 million aggregate principal amount of convertible notes outstanding as of the date of this prospectus, which includes $20.0 million principal amount of notes issued subsequent to March 31, 2017, and (iii) 968,182 shares of our common stock to be issued to Hanmi and certain of our executive officers upon the completion of this offering pursuant to contractual obligations discussed elsewhere in this prospectus.

from December 31, 2016 to March 31, 2017 Stock options and warrants exercised Repurchase of common stock

from December 31, 2015 to December 31, 2016 Issuance of common stock Issuance of common stock in connection with satisfaction of contingent consideration Vesting of restricted stock Stock options and warrants exercised Repurchase of common stock